CHARLOTTE, NC — People with moderate-to-severe ulcerative colitis benefit from stronger treatment from the start — a combination of monoclonal antibodies — compared with induction with either agent ...

June 16, 2009 (Copenhagen, Denmark) — The benefits of golimumab reported at 24 weeks by patients with psoriatic arthritis in the GO-REVEAL study persisted at 2 years, according to the results of a 104 ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — According to findings presented at the American College of Rheumatology Annual Meeting, 75% of ...

Please provide your email address to receive an email when new articles are posted on . The occurrence rate and disease activity of acute anterior uveitis in ankylosing spondylitis decreased ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of golimumab, having considered evidence on the nature of rheumatoid arthritis and the value placed on the ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis BOSTON, Nov. 7 -- Patients with active psoriatic ...

BOSTON, Nov. 7 More than half of patients receivingmonthly subcutaneous (SC) injections of golimumab (CNTO 148) 50 mg and 100 mgexperienced significant and sustained improvements in the signs and ...

The appraisal committee (section 5) considered evidence submitted by Merck Sharp & Dohme and a review of this submission by the evidence review group (ERG). See the committee papers for full details ...

On February 10, 2025, Bio-Thera Solutions, Ltd. announced that they entered into an exclusive licensing agreement with Intas Pharmaceuticals Ltd. to commercialize BAT2506 (golimumab), Bio-Thera’s ...

Review the side-effects of Golimumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

REYKJAVIK, ICELAND (December 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today ...